UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 223

Sortiert nach

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Annals of oncology, 2016-09, Vol.27 (9), p.1746-1753

2016

Volltextzugriff (PDF)

Cetuximab plus oxaliplatin leucovorin 5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

British journal of cancer, 2010-02, Vol.102 (3), p.500-505

2010

Volltextzugriff (PDF)

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

Annals of oncology, 2013-06, Vol.24 (6), p.1580-1587

2013

Volltextzugriff (PDF)

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial

Annals of oncology, 2016-12, Vol.27 (12), p.2203-2209

2016

Volltextzugriff (PDF)

Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies

Annals of oncology, 2019-07, Vol.30, p.iv116-iv116

2019

Volltextzugriff (PDF)

Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study – AIO SUP-0108

European journal of cancer (1990), 2016-08, Vol.63, p.127-134

2016

Volltextzugriff (PDF)

Exploratory biomarker analysis in patients treated with vinorelbine plus everolimus or vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer: Final results from the randomized phase II trial VicTORia

Annals of oncology, 2018-10, Vol.29, p.viii94-viii94

2018

Volltextzugriff (PDF)

Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217)

Annals of oncology, 2018-10, Vol.29, p.viii265-viii266

2018

Volltextzugriff (PDF)

Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients

British journal of cancer, 2008-09, Vol.99 (6), p.930-938

2008

Volltextzugriff (PDF)

PD-008Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii104-ii104

2016

Volltextzugriff (PDF)

Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group

Annals of oncology, 2013-12, Vol.24 (12), p.3051-3055

2013

Volltextzugriff (PDF)

402 Clinical performance comparison of RAS mutation detection in plasma and tissue samples from stage IV colorectal cancer patients for first-line anti-EGFR therapy selection

European journal of cancer (1990), 2015-09, Vol.51, p.S79-S79

2015

Volltextzugriff (PDF)

2333 Trastuzumab in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastro- oesophageal junction cancer: Updated findings from the German non-interventional study HerMES

European journal of cancer (1990), 2015-09, Vol.51, p.S444-S444

2015

Volltextzugriff (PDF)

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2023-06, Vol.388 (22), p.2058-2070

2023

Volltextzugriff (PDF)

A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer

Annals of oncology, 2011-03, Vol.22 (3), p.603-608

2011

Volltextzugriff (PDF)

Pleural effusion of a second neoplasm in a patient with B‐CLL: Two immunological compartments

American journal of hematology, 2003-07, Vol.73 (3), p.184-189

2003

Volltextzugriff (PDF)

Frühes Mammakarzinom

Der Onkologe, 2021-12, Vol.27 (12), p.1152-1155

2021

Volltextzugriff (PDF)

Exacerbation of antiphospholipid antibody syndrome after treatment of localized cancer: a report of two cases

Annals of hematology, 2002-12, Vol.81 (12), p.727-731

2002

Volltextzugriff (PDF)

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

Journal of clinical oncology, 2008-03, Vol.26 (9), p.1435-1442

2008

Volltextzugriff (PDF)

Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells

Journal of Virology, 1995-12, Vol.69 (12), p.7541-7547

1995

Volltextzugriff (PDF)

Current status of radiant whole-body hyperthermia at temperatures >41.5°C and practical guidelines for the treatment of adults. The German 'Interdisciplinary Working Group on Hyperthermia'

International journal of hyperthermia, 2005-03, Vol.21 (2), p.169-183

2005

Volltextzugriff (PDF)

No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer

Annals of oncology, 1998-01, Vol.9 (1), p.85-93

1998

Volltextzugriff (PDF)

Whole-body hyperthermia (41.8°C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study

Annals of oncology, 2002-08, Vol.13 (8), p.1197-1204

2002

Volltextzugriff (PDF)

1 – 25 von 223

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(213)
Mit Volltextzugriff
(208)

Publikationsform

Sprache

Englisch
(202)
Deutsch
(21)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(103)
Science & Technology
(103)
Humans
(97)
Oncology
(82)
Female
(62)
Male
(57)
Middle Aged
(57)
Adult
(46)
Aged
(46)
Biological And Medical Sciences
(41)
Medical Sciences
(39)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(31)
Tumors
(30)
Chemotherapy
(29)
Colorectal Cancer
(23)
Pharmacology. Drug Treatments
(23)
Antineoplastic Agents
(22)
Hematology
(22)
Aged, 80 And Over
(21)
Cancer
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Cetuximab plus oxaliplatin leucovorin 5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial

Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies

Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study – AIO SUP-0108

Exploratory biomarker analysis in patients treated with vinorelbine plus everolimus or vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer: Final results from the randomized phase II trial VicTORia

Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217)

Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients

PD-008Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study

Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group

402 Clinical performance comparison of RAS mutation detection in plasma and tissue samples from stage IV colorectal cancer patients for first-line anti-EGFR therapy selection

2333 Trastuzumab in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastro- oesophageal junction cancer: Updated findings from the German non-interventional study HerMES

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer

Pleural effusion of a second neoplasm in a patient with B‐CLL: Two immunological compartments

Frühes Mammakarzinom

Exacerbation of antiphospholipid antibody syndrome after treatment of localized cancer: a report of two cases

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells

Current status of radiant whole-body hyperthermia at temperatures >41.5°C and practical guidelines for the treatment of adults. The German 'Interdisciplinary Working Group on Hyperthermia'

No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer

Whole-body hyperthermia (41.8°C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study

Suchergebnisse filtern